论文部分内容阅读
目的检测协同刺激分子B7-H3在肝细胞癌患者血清及组织中的表达,并探讨其临床意义。方法选取原发性肝细胞癌63例患者的癌组织和血清标本;5例肝血管瘤的瘤旁组织作为正常肝组织对照;同期收取50例健康体检人员外周血标本为正常对照。采用ELISA检测肝癌患者和正常人血清中可溶型B7-H3(sB7-H3)的含量,免疫组化检测正常肝组织和肝细胞癌组织中B7-H3的表达。结果肝细胞癌患者外周血清sB7-H3含量为(4143.47±976.27)pg/mL,显著高于正常对照组(2076.18±605.42)pg/mL(P<0.05);且其表达水平与临床分期,是否远处转移及肝癌组织中是否阳性表达B7-H3等参数有关(P<0.05),与年龄、性别、组织学类型、淋巴结转移及肿瘤大小等临床病理参数无关;与血清学指标CA19-9呈明显正相关(P<0.05),但与AFP和CEA水平无相关性。结论肝癌患者血清中sB7-H3表达明显高于正常人,B7-H3表达与疾病临床病理指标相关,表明检测sB7-H3可能对原发性肝癌的诊断有一定价值。
Objective To detect the expression of costimulatory molecule B7-H3 in the serum and tissues of patients with hepatocellular carcinoma and to explore its clinical significance. Methods Tumor tissues and serum samples from 63 patients with primary hepatocellular carcinoma were selected. The tumor-adjacent tissues of 5 hepatic hemangiomas served as controls for normal liver tissues. Peripheral blood samples from 50 healthy volunteers were collected as normal controls. The levels of soluble B7-H3 (sB7-H3) in sera of patients with hepatocellular carcinoma and normal controls were detected by ELISA. The expression of B7-H3 in normal liver tissue and hepatocellular carcinoma was detected by immunohistochemistry. Results The level of sB7-H3 in peripheral blood of patients with hepatocellular carcinoma was (4143.47 ± 976.27) pg / mL, which was significantly higher than that of the normal control group (2076.18 ± 605.42) pg / mL (P <0.05) Distant metastasis and the expression of B7-H3 in hepatocellular carcinoma (P <0.05), but not with clinicopathological parameters such as age, sex, histological type, lymph node metastasis and tumor size. Serum CA19-9 (P <0.05), but not with the levels of AFP and CEA. Conclusion The expression of sB7-H3 in serum of hepatocellular carcinoma patients is obviously higher than that of normal persons. The expression of B7-H3 is correlated with the clinicopathological parameters of the disease, indicating that the detection of sB7-H3 may be of value in the diagnosis of primary liver cancer.